3.99 USD
▲+0.06+1.53%
盘后 4.13 0.00%
2026-11-20
市值
$318.00M
市盈率
—
EPS
-1.96
股息率
—
52 周区间
2.93 – 6.45
成交量
180.62K
Beta
0.72
目标价
9.00
52W 低 2.9352W 高 6.45
价格走势
公司简介
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ...